http://www.fnarena.com/index2.cfm?type=dsp_newsitem&n=EB42AF6D-DC17-9644-ECDC6F7D04986032 $1 target price
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%